Skip to main content
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 2012 Aug 6;109(34):13584-13589. doi: 10.1073/pnas.1211550109

Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition

Rainer Wilcken 1,1, GuoZhen Wang 1,1, Frank M Boeckler 1,2, Alan R Fersht 1,3
PMCID: PMC3427094  PMID: 22869713

Abstract

Aggregation of destabilized mutants of the tumor suppressor p53 is a major route for its loss of activity. In order to assay drugs that inhibit aggregation of p53, we established the basic kinetics of aggregation of its core domain, using the mutant Y220C that has a mutation-induced, druggable cavity. Aggregation monitored by light scattering followed lag kinetics. Electron microscopy revealed the formation of small aggregates that subsequently grew to larger amorphous aggregates. The kinetics of aggregation produced surprising results: progress curves followed either by the binding of Thioflavin T or the fluorescence of the protein at 340 nm fitted well to simple two-step sequential first-order lag kinetics with rate constants k1 and k2 that were independent of protein concentration, and not to classical nucleation-growth. We suggest a mechanism of first-order formation of an aggregation competent state as being rate determining followed by rapid polymerization with the higher order kinetics. By measuring the inhibition kinetics of k1 and k2, we resolved that the process with the higher rate constant followed that of the lower. Further, there was only partial inhibition of k1 and k2, which showed two parallel pathways of aggregation, one via a state that requires unfolding of the protein and the other of partial unfolding with the ligand still bound. Inhibition kinetics of ligands provides a useful tool for probing an aggregation mechanism.

Keywords: amyloid, misfolding, folding, cancer


The most frequently mutated gene in cancer is that of the tumor suppressor p53. Some 70% of types of human cancers have their p53 directly inactivated by mutation, and so its reactivation is an important therapeutic goal (1). The most common oncogenic mutations are of residues in the DNA binding domain (DBD, residues 94–312) that make direct contact with DNA (2). But about 30%–40% of oncogenic mutants are inactivated because the mutations lower the stability of the DBD so that it denatures at body temperature, although it can be fully active at lower temperatures (36). We are attempting to rescue those temperature-sensitive mutants of p53 by designing small molecules that bind specifically to the native state of the protein and stabilize it (7). The rationale is that small molecules that bind to the native state of a temperature-sensitive mutant and not the denatured states will raise the melting temperature by a mass action effect. Such a molecule will slow down the rate of unfolding if it binds weakly to the transition state for unfolding. The obvious binding sites to target are those already present that bind natural ligands. In theory, they can be targeted in a chaperone strategy in which a rescue drug will compete for a binding site (7). We have chosen, instead, as a particularly useful paradigm for these studies, the stability of the p53 mutant Y220C, because the mutation induces a druggable cavity that is remote from functional areas of the protein (8, 9). We have designed small molecules that raise the apparent Tm of Y220C and slow down the initial rate of denaturation by a factor of 3 or 4 (8). But the loss of activity of p53 is more complicated than simple denaturation, and the further design and refinement of putative leads requires a deeper understanding of the process and how to target it.

Early cell-based studies found that p53 forms high molecular weight aggregates in transformed cells and other cells (1012). Biophysical studies in vitro found the inactivation of p53 and its mutants by denaturation involves the initial reversible unfolding of the core domain to give an intermediate, which then aggregates irreversibly by classical nucleation-growth lag kinetics (3, 4, 6, 13) and gives aggregates of various morphologies, including amorphous, fibrillar, and prionoid, according to the means of preparation (14, 15). The fluorescence of the single tryptophan residue, Trp146, in the native state is highly quenched, but in the denatured state has a strong emission at 356 nm and an aggregated state even stronger at 340 nm (3). The aggregate of wild-type p53 forms reversibly during urea-mediated denaturation or irreversibly during thermal denaturation or the presence of EDTA, and more readily with destabilized mutants (3). As destabilized mutants unfold and then aggregate faster than wild type, it was suggested that the phenomenon of negative dominance of unstable mutants cotranslated with wild-type protein (16) results from the denatured mutant nucleating the aggregation of wild type in mixed hybrids (5). An in-depth study has characterized nucleation of p53 in cells, identified a nucleation-prone sequence in its core domain, which also nucleates the aggregation of p63 and p73, and leads to coaggregates in cell lines (17).

Native-state stabilization can inhibit aggregation of p53 (3, 4) and proteins in general. (18) In order to design and assay novel, mutant-specific anticancer drugs that can inhibit the aggregation of Y220C, we have analyzed the kinetics of aggregation of the mutant and found it fits a very simple scheme. We have used novel binding ligands (19) as tools to probe the biophysics of denaturation and aggregation in vitro and the structural requirements for inhibition of aggregation. We have found candidates for molecules that can reactivate Y220C in a cancer cell line.

Results

All experiments were performed on the core domain of Y220C in the framework of the stabilized quadruple mutant of p53 (9). It has an approximate midpoint for denaturation of 44.5 °C on rapid heating by differential scanning calorimetry (8). We measured the aggregation of Y220C at 37 °C by a combination of methods.

Kinetics of Aggregation.

Kinetics of aggregation from light scattering.

Aggregation was measured at 37 °C, by monitoring light scattering at 500 nm (Fig. 1A). There was an initial lag period, which is usually taken as indicating nucleation events taking place; a growth period; and then a leveling off as substrate was depleted. The lag time shortened with increasing concentrations of p53. This was also shown by monitoring the absorbance at 360 nm (Fig. 1C). Light scattering is greatly weighted to the contribution of large aggregates, as the magnitude of Rayleigh scattering varies as the size raised to the power of 6, which overemphasizes the lag.

Fig. 1.

Fig. 1.

Aggregation kinetics of the core domain of p53Y220C at different concentrations at 37 °C. Panes (A), (B), and (C) monitor aggregation by right-angle light scattering, ThT binding, and absorbance, respectively. (D) Kinetics monitored by ThT values where the ThT intensity values are normalized to concentration of p53. Visible particulates appear after the lag phase and cause random noise in the signals. The time courses for ThT (20 μM) binding were fitted to Eq. 1 with a very small linear drift term (solid lines through curves). ThT was not present in the scattering experiments, but controls show it has insignificant effects (Fig. S2B). The y-axes for (A), (B), and (D) are in arbitrary units, and absorbance units for (C).

Kinetics of aggregation from thioflavin T binding.

Thioflavin T (ThT) binds to amyloid fibrils, and can give a good signal that is relatively independent of size and so shows early aggregation events that precede the formation of large aggregates (14, 20, 21). Indeed, the lag was considerably reduced (Fig. 1B). Normalizing the ThT signal to the concentration of p53 (Fig. 1D) showed that the amplitude of the signal was constant, and not dependent on the size of particles, in contrast to light scattering. Remarkably, the kinetics fitted to the very simple Scheme 1 of a two-step reaction of sequential first-order reactions (where A is the monomeric protein, B is a monomeric intermediate, and C is a product that has the ThT-fluorescence signal), which has the solution Eq. 1 for the formation of C (22)

Scheme 1.

Scheme 1.

graphic file with name pnas.1211550109eq1.jpg [1]

In practice, we fitted the data to:

graphic file with name pnas.1211550109eq2.jpg [2]

where Ft is the intensity of ThT fluorescence at time t, and m, the amplitude, = [A]0f, where f is the specific fluorescence of ThT bound to the aggregate. A small linear drift term of k3t was added to Eq. 1 to allow for any drift in signal strength because of machine drift or slow settling of particles. k3 was close to zero. Note that Eq. 1 is unchanged if k1 and k2 are interchanged, so we cannot assign from the curve fitting whether the numerically greater rate constant precedes the lower or vice versa. We solve the assignment problem later in this paper from inhibition studies.

The values of k2 and k1 in min-1 derived from the fits to Eq. 2 were, respectively: 3 μM p53, 0.32 ± 0.03 and 0.064 ± 0.0016; 6 μM, 0.36 ± 0.02 and 0.067 ± 0.001; 9 μM, 0.37 ± 0.03 and 0.063 ± 0.0007; and 12 μM, 0.37 ± 0.015 and 0.071 ± 0.007 (means and standard errors for single runs). Both rate constants were virtually independent of protein concentration. The residuals between calculated curves and data are good (Fig. S1). There may be a low amplitude faster phase that we missed in the analysis, possibly that of the initial unfolding of the protein prior to slower aggregation events. But the above equation accounts for the major phases of aggregation. The mean and standard error for 9 measurements at 3 μM protein in the inhibition experiments below gave 0.314 ± 0.018 and 0.0545 ± 0.0017 min-1.

Fluorescence spectra and kinetics.

Fluorescence spectra at various time points during aggregation (Fig. 2A) showed apparently only two major fluorescent species during the process: the native protein (λmax = 305 nm) being lost and the aggregate state (λmax = 340 nm) being formed with an isoemission wavelength of 314 nm and with the same rate constants (Fig. 2C). The process is not simple denaturation of Y220C, since the experiments were at 7.5 °C below its Tm and the fluorescence spectrum of the product is not that of the denatured state. [The denatured state has λmax = 356 nm (3, 4) and Fig. 2B.] The kinetics of fluorescence 340 nm also fitted reasonably well to Eq. 1 to give similar values of k2 and k1 in min-1: 1 μM p53, 0.20 ± 0.01 and 0.084 ± 0.0009; 2 μM, 0.47 ± 0.02 and 0.067 ± 0.0006; 3 μM, 0.45 ± 0.02 and 0.066 ± 0.0006; and 5 μM, 0.61 ± 0.04 and 0.074 ± 0.006. The formation of large aggregates causes the noise in the latter stages of all the kinetic runs and a slow decrease in signal (Fig. 2D). The mean rate constants are 0.43 ± 0.08 and 0.073 ± 0.004 min-1, averaged from the singles runs at each concentration.

Fig. 2.

Fig. 2.

Changes in fluorescence spectra of p53 with time on incubation at 37 °C. (A) Repetitive scans on excitation at 280 nm show an isofluorescence point at 314 nm and movement to λmax = 340 nm with time. (B) The fluorescence spectrum of denatured p53 Y220C. (C) The loss of native tyrosine fluorescence at 305 nm paralleled the increase in aggregated state fluorescence at 340 nm during those scans for different concentrations of p53. (D) The increase in fluorescence monitored at 340 nm was fitted to Eq. 1, with a linear drift term (solid lines).

ThT has minimal perturbation of kinetics.

The near coincidence of ThT and 340-nm kinetic data strongly suggests that ThT does not affect the kinetics significantly. We showed directly that varying ThT between 5–20 μM has minimal effects on 340 nm-monitored kinetics (Fig. S2A) and on light scattering (Fig. S2B). The rate constants for ThT kinetics remained constant within experimental error between 5 and 25 μM (Fig. S2C), but the amplitudes increased, fitting a binding isotherm of 10 ± 0.6 μM (Fig. S2D), indicating a reversible binding of ThT. We discuss further in the accompanying paper why different techniques give different kinetics (23).

Lack of seeding by aggregated Y220C.

Nucleation mechanisms are characterized by being seeded by already aggregated protein. (24) The addition of 1 μM aggregated Y220C to 2 μM fresh p53 (Fig. S3A) had only a small effect on light scattering relative to that of 2 μM fresh protein alone, and the initial rate was similar to that of 3 μM fresh protein. The addition of 1 μM aggregated Y220C to 2 μM fresh p53 monitored by ThT fluorescence (Fig. S3B) gave no detectable change in the kinetics.

Electron microscopy studies.

During the lag period, we saw only tiny particles in electron micrographs. These covered much of the grid, but during the growth period they progressively coalesced to form amorphous aggregates that grew larger with increasing time (Fig. S4A, and see electron microscopy studies of inhibition below, Fig. S4B).

Kinetic Analysis of Inhibition of Aggregation.

We analyzed the inhibition of aggregation by examples from two classes of drug leads: PK083 (8), a carbazole derivative, and four new leads, PK5174, PK5176, PK5196, and PK5201 (abbreviated to 83, 5174 etc.), which are designed to occupy a more extended binding site (19) (Fig. S5).

Light scattering.

The effects of potential drugs on aggregation were monitored at 500 nm to avoid any light absorbance by them. The addition of 5174 at up to 120 μM significantly inhibited aggregation (Fig. 3A). However, the shape of the curve changed with increasing concentration, having a sloping phase before leveling off. Such curves can be fitted to empirical equations. Following the procedure of Wetzel and coworkers (25, 26), we used a simple model-free method and plotted the initial rates of scattering against t2, where t is time [a generally useful plot (27)]. The rate of addition of monomer to growing oligomers varies as t2 and the slope of the plot is V0. If a ligand binds to the protein with dissociation constant KI and the protein-ligand complex is fully inhibited from aggregation, V0 depends on the concentration of unbound protein and is given by:

graphic file with name pnas.1211550109eq3.jpg [3]
Fig. 3.

Fig. 3.

Inhibition of light scattering kinetics by ligands 5174 (A, C) and 5201 (B, D); measurements done with 3 μM protein, 37 °C, standard buffer.

More generally, if the ligand-bound protein also aggregates with an initial rate of V0BL, then:

graphic file with name pnas.1211550109eq4.jpg [4]

The slopes of the inhibition plots plotted against concentrations of ligand fitted saturation curves, with V0BL being undetectably small. Variation of 5174 (Fig. 3A) gave a KI of 19 ± 4 μM (Fig. 3C). Compound 5201 was particularly effective: the calculated KI = 6 ± 1 μM, and the lag period for aggregation at 120 μM drug was increased to nearly an hour (Fig. 3B and D). Similar plots were performed for other ligands (Fig. S6).

Thioflavin T binding.

The rate of increase of fluorescence of ThT was inhibited by the ligands and gave curves that could individually be well fitted to Eq. 2 (Fig. S7). The inhibition of k1 (Fig. 4) and k2 (Fig. 5) fitted to simple binding isotherms that did not tend to zero as the concentration of ligand increased. We first fitted the data to Eq. 4 (substituting k for V0) without any constraints. The curves generated large standard errors (Table 1), so we then refitted assuming a common value for k1 in the absence of ligand, the average of all the curves (0.0557 ± 0.002 min-1), and for the value for ligand-bound protein (0.0187 ± 0.0027 min-1), so that the only variable was the constant KI (Fig. 4). The values thus derived were similar to the free-fitted, but with much better standard errors (Table 1). These values were very similar to those measured directly by isothermal titration calorimetry (ITC). (19) The same was done for k2 using values of (0.319 ± 0.001 min-1) and for the value for ligand-bound protein (0.055 ± 0.015 min-1, Fig. 5), to generate values of KI that were, generally, significantly higher, apart from 5176, where the data were poorer.

Fig. 4.

Fig. 4.

Inhibition of the rate constant k1 in ThT binding kinetics by ligands fitted to the equation k1 = k1BL + (k1 max - k1BL)KI/(KI + [L]), where k1 max is constrained to 0.0557 and k1BL to 0.0187 min-1, respectively.

Fig. 5.

Fig. 5.

Inhibition of the rate constant k2 in ThT binding kinetics by ligands fitted to the equation k2 = k2BL + (k2 max - k2BL)KI/(KI + [L]), where k2 max is constrained to 0.319 and k2BL to 0.055 min-1 respectively.

Table 1.

Inhibition of aggregation Y220C measured by different techniques

Inhibitor KI [μM] k1 (ThT) free fit KI [μM] k1 (ThT) constrained KI [μM] k2 (ThT) free fit KI [μM] k2 (ThT) constrained KI [μM] k1k2 (ThT) KI[μM] k1k2 (340 nm) KI[μM] V0 (scatter) KD [μM] native state (ITC)
PK83 -* -* -* 95 ± 30 96 ± 3 125
PK5174 15 ± 9 15 ± 4 27 ± 15 25 ± 5 15 ± 1 31 ± 4 19 ± 4 16
PK5176 61 ± 60 31 ± 10 10 ± 11 16 ± 8 13 ± 7 37 ± 7 35 ± 4 21
PK5196 6.4 ± 1.7 8.6 ± 1 42 ± 22 35 ± 5 13 ± 1 20 ± 4 10 ± 1 10
PK5201 3 ± 2 5 ± 1 15 ± 8 23 ± 6 5.1 ± 0.8 7 ± 3 6 ± 1 8

*PK83 interacts with Thioflavin T, which masks its binding. ITC measured at 20 °C. Stoichiometry = 1 mol ligand/mol protein.

The product of the two rate constants k1k2 also fitted a simple isotherm. The initial rate of aggregation, according to Eq. 1 as t tends to 0, is given by: V0 = 0.5k1k2t2[A]0. That equation is analogous to that for the initial rate of the light scatter plots. The initial rate of increase of ThT fluorescence versus t2 may be derived from the product of k1 and k2 measured from the lag kinetics. A plot of k1k2 versus [ligand] is analogous to Eqs. 3 and 4 for calculating a KD for inhibition (Fig. 6). The derived values were close to those obtained from ITC (Table 1). We could not analyze the data for the binding of 83 because it binds to ThT.

Fig. 6.

Fig. 6.

Inhibition of the rate constant k1k2 in ThT binding kinetics by ligands fitted to the equation k1k2 = (k1k2)BL + ((k1k2)max - (k1k2)BL)KI/(KI + [L]).

340 nm fluorescence.

The kinetics of appearance of aggregate was followed by fluorescence at 340 nm. The absorbance of the ligands at the excitation wavelength as well as the emission caused significant loss of signal at higher concentrations, so the data were less accurate. But the same trends as for the ThT-monitored kinetics were observed, and the limited analysis of k1k2 gave dissociation constants consistent with the other methods (Table 1).

Electron microscopy.

140 μM 5174 and 400 μM 83 inhibited the formation and growth of aggregates in good qualitative agreement with the light scattering studies (Fig. S4B).

Discussion

Complex Kinetics Fits to a Simple Equation Other Than Classical Nucleation Growth.

p53Y220C core domain aggregates at 37 °C, some 7 °C below its temperature of reversible denaturation. The kinetics of ThT fluorescence and intrinsic tryptophan fluorescence at 340 nm monitoring the aggregation of p53Y220C fitted well to two apparent sequential first-order rate constants, 0.3 and 0.06 min-1, which are independent of concentration in the concentration range measured (1–12 μM protein) (Figs. 1 and 2). That behavior is strikingly different from standard nucleation-growth kinetics for protein aggregation, which is usually complex and involves rate constants for formation of a nucleus and with higher-order concentration terms for growth. But simple first-order aggregation kinetics has been observed previously. (2830) Electron microscopy revealed an initial formation of small particles that increased in size to form an amorphous aggregate over the same time frame as the spectral changes (Fig. S4), rather than well-formed fibrils. Neither the individual progress curves nor their dependence on concentration fit a standard nucleation-growth model as the rate constants are simple first order and do not increase with concentration of protein.

We tried fitting it to the simplest model of protein aggregation, the 2-step mechanism of slow, continuous nucleation followed by fast growth (Scheme 2), analyzed by Finke and Watzky (31), who have comprehensively compared it with other models (32).

Scheme 2.

Scheme 2.

The analytical solution of Scheme 2 is (31):

graphic file with name pnas.1211550109eq5.jpg [5]

It can be convenient to eliminate A from the equations, so let k2A0 = k2(app)

graphic file with name pnas.1211550109eq6.jpg [6]

The aggregation kinetics of p53 Y220C monitored by ThT fluorescence appears to fit to Eq. 6 at each individual concentration (Fig. S8A), but not as well as for the simple 2-step lag kinetics, as shown from the residuals to the fits (Fig. S8B). We can rule out conclusively the Finke–Watzky mechanism from the concentration dependence of the rate constants: the term k2(app), = k2A0, in Eq. 6 should increase linearly from 0 with the concentration of A0, but is independent of concentration from 3 to 12 μM protein (Fig. S8D). There is also no significant seeding of aggregation (Fig. S3).

Vitalis and Pappu (27) have analyzed the significance of slopes of initial rates of scattering, etc., versus t2, V0, versus concentration of monomer. The slope for homogeneous nucleation with n molecules in the nucleus should be n + 2. The measured slope of 1 (Fig. S9) is indicative of either a heterogeneous distribution of nuclei or of a secondary process that we have identified to be a first-order conformational transition to a species that is capable of supporting polymerization. And more importantly, the data and the inferred rate constants are consistent with such a unimolecular process.

Kinetics of Inhibition.

The basic conclusion is that ligands that bind to the mutation-induced cavity in Y220C inhibit its aggregation, with initial rates being as expected from the dissociation constants. In addition, the kinetics of inhibition has provided invaluable mechanistic information. The rate constants k1 and k2 for ThT binding are inhibited by compounds 5174, 5176, 5196, and 5201 such that each inhibition profile fits a simple binding isotherm with a finite limiting value at saturating concentrations of ligand. The lack of complete inhibition could result from there being two populations of protein, one of which does not bind the ligand. But ITC shows a stoichiometry of 1∶1 ligand bound to protein. (19) The remaining alternative is that ligand-bound protein can still aggregate, albeit at a much reduced rate.

Basic Aggregation Mechanism.

The first-order kinetics implies that the rate determining steps in the process are the first-order formation of an aggregation-competent state that can rapidly polymerize so that the higher-order steps are after the rate-determining ones. We have analyzed simple schemes (SI Text, Schemes S1–S3) to see if they could account for the inhibition behavior and the first-order sequential kinetics. The simplest is given in Scheme 3.

Scheme 3.

Scheme 3.

The ligands can bind to states A and B, and the A.L and B.L states also aggregate via an aggregation-competent state C, which may possibly also polymerize when bound to L. So p53 can aggregate by complete unfolding, which is inhibited by the binding of ligands, or by partial unfolding with the ligand still bound.

Order of Rate Constants.

Eq. 3 for sequential kinetics is symmetrical with respect to exchange of k1 and k2, and so unless the concentration of B is also measured, we do not know whether the higher rate constant precedes the lower or vice versa. But the values of KA and KB can be used to deconvolute the order: KA should be the same as the independently measured value of the dissociation constant from the protein. As seen in Table 1, it is the lower rate constant that is inhibited, with a value of KA similar to that measured by ITC, and so represents the first process. Accordingly, k1, k1A.L, k2, k1B.L in Scheme 3, are 0.0557 ± 0.002, 0.0187 ± 0.0027, 0.319 ± 0.001, 0.055 ± 0.015 min-1, respectively.

In the accompanying paper, (23) we explore the consequences of the proposed mechanism for the aggregation of the core domain of Y220C and show the mechanism extends to the full-length protein.

Methods

Chemical Compounds.

PK083 (= 83, EN300–14607) was purchased from Enamine and > 95% pure. PK5174, PK5176, PK5196 and PK5201 were synthesized within the framework of a custom synthesis contract by Roowin S.A. For all compounds, compound identity and > 95% purity were guaranteed by the supplier.

Protein Expression and Purification.

The thermostabilized Y220C protein was expressed and purified as described (8).

Isothermal Titration Calorimetry (ITC).

ITC experiments were conducted using a MicroCal iTC200 calorimeter. Protein samples used in the cell unit were prepared to a final concentration of 50–200 μM in 25 mM potassium phosphate, pH 7.2, 150 mM NaCl, 1 mM tris(2-carboxyethyl)phosphine hydrochloride (TCEP) in 5% (v/v) DMSO. Compounds for use in the syringe unit were dissolved in the same buffer at 5% (v/v) DMSO. Measurements were performed at 20 °C using injection steps of 2 μL at 0.5 μL/s (initial injection: 0.5 μL) and 120 s spacing. Data analysis was performed using MicroCal Origin software.

Kinetics of Aggregation.

Light scattering.

To measure the effect of compounds on the kinetics of aggregation of Y220C, we monitored protein aggregation by measuring light scattering at 37 °C at 500 nm as excitation and emission wavelengths (excitation slit width 0.8 nm, emission slit width 2 nm), using a Horiba FluoroMax-3 spectrophotometer. Experiments were generally performed with a protein concentration of 3 μM in 25 mM potassium or sodium phosphate, pH 7.2, 150 mM NaCl, 5 mM DTT or 1 mM TCEP, and 5% DMSO. The kinetics at the single wavelength of 340 nm was measured using the same setup as light scattering above, but excitation and emission wavelengths were set to 285 nm and 340 nm, respectively, with slit widths set to 3 nm (excitation) and 4 nm (emission). To obtain homogenous mixing, Scienceware (Bel-Art Products) spectrometer cell spinbars were used. Effects of aggregation seeds were minimized using disposable Fisher Scientific UV grade PMMA cuvettes and storing the spinbars in nitric acid when not in use. Data analysis was performed using KaleidaGraph (Synergy Software).

Thioflavin T assays.

As for detecting other amyloid aggregates, we measured the ThT fluorescence at 482 nm upon excitation at 450 nm (33) (excitation/emission slits are 3 nm/4 nm) using a Horiba FluoroMax-3 Spectrofluorometer. Time-resolved fluorescence was recorded immediately after adding 3 μM Y220C to pre-equilibrated buffer (25 mM sodium phosphate, pH 7.2, 150 mM NaCl, 1 mM TCEP, 5% DMSO, 20 μM ThT).

Time-resolved fluorescence spectra.

The intrinsic fluorescence spectra of Y220C (excited at 280 nm, emission between 300 nm and 500 nm) were recorded with a Horiba FluoroMax-4 Spectrofluorometer immediately after the addition of protein to pre-equilibrated buffer (25 mM sodium phosphate, pH 7.2, 150 mM NaCl, 1 mM TCEP, 5% DMSO). Both the slits for excitation and emission were 5 nm.

Transmission Electron Microscopy.

Y220C (3 μM) was incubated at 37 °C with or without the compounds in 25 mM Tris-HCl, pH 7.2, 150 mM NaCl, 1 mM TCEP, and 5% DMSO. Samples were taken at different time points. The samples (5 μL) were adsorbed to freshly glow-discharged formvar or carbon film 400 mesh copper grids, rinsed with deionised water, and stained with 1% uranyl acetate or sodium phosphotungstate. Images were taken using a Phillips 208S transmission electron microscope at 80 kV.

Supplementary Material

Supporting Information

ACKNOWLEDGMENTS.

This work was funded by an ERC Advanced Grant to A.R.F.

Footnotes

The authors declare no conflict of interest.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1211550109/-/DCSupplemental.

References

  • 1.Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: Drugging the p53 pathway. Nat Rev Cancer. 2009;9:862–873. doi: 10.1038/nrc2763. [DOI] [PubMed] [Google Scholar]
  • 2.Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science. 1994;265:346–355. doi: 10.1126/science.8023157. [DOI] [PubMed] [Google Scholar]
  • 3.Bullock AN, et al. Thermodynamic stability of wild-type and mutant p53 core domain. Proc Natl Acad Sci USA. 1997;94:14338–14342. doi: 10.1073/pnas.94.26.14338. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Bullock AN, Henckel J, Fersht AR. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: Definition of mutant states for rescue in cancer therapy. Oncogene. 2000;19:1245–1256. doi: 10.1038/sj.onc.1203434. [DOI] [PubMed] [Google Scholar]
  • 5.Bullock AN, Fersht AR. Rescuing the function of mutant p53. Nat Rev Cancer. 2001;1:68–76. doi: 10.1038/35094077. [DOI] [PubMed] [Google Scholar]
  • 6.Friedler A, Veprintsev DB, Hansson LO, Fersht AR. Kinetic instability of p53 core domain mutants: Implications for rescue by small molecules. J Biol Chem. 2003;278:24108–24112. doi: 10.1074/jbc.M302458200. [DOI] [PubMed] [Google Scholar]
  • 7.Friedler A, et al. A peptide that binds and stabilizes p53 core domain: Chaperone strategy for rescue of oncogenic mutants. Proc Natl Acad Sci USA. 2002;99:937–942. doi: 10.1073/pnas.241629998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Boeckler FM, et al. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci USA. 2008;105:10360–10365. doi: 10.1073/pnas.0805326105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Joerger AC, Ang HC, Fersht AR. Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc Natl Acad Sci USA. 2006;103:15056–15061. doi: 10.1073/pnas.0607286103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Kraiss S, Spiess S, Reihsaus E, Montenarh M. Correlation of metabolic stability and altered quaternary structure of oncoprotein p53 with cell transformation. Exp Cell Res. 1991;192:157–164. doi: 10.1016/0014-4827(91)90170-y. [DOI] [PubMed] [Google Scholar]
  • 11.Kraiss S, Quaiser A, Oren M, Montenarh M. Oligomerization of oncoprotein p53. J Virol. 1988;62:4737–4744. doi: 10.1128/jvi.62.12.4737-4744.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.McCormick F, Clark R, Harlow E, Tjian R. SV40 T antigen binds specifically to a cellular 53 K protein in vitro. Nature. 1981;292:63–65. doi: 10.1038/292063a0. [DOI] [PubMed] [Google Scholar]
  • 13.Butler JS, Loh SN. Structure, function, and aggregation of the zinc-free form of the p53 DNA binding domain. Biochemistry. 2003;42:2396–2403. doi: 10.1021/bi026635n. [DOI] [PubMed] [Google Scholar]
  • 14.Ishimaru D, et al. Fibrillar aggregates of the tumor suppressor p53 core domain. Biochemistry. 2003;42:9022–9027. doi: 10.1021/bi034218k. [DOI] [PubMed] [Google Scholar]
  • 15.Ano Bom AP, et al. Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: Implications for cancer. J Biol Chem. 2012 doi: 10.1074/jbc.M112.340638. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Milner J, Medcalf EA. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell. 1991;65:765–774. doi: 10.1016/0092-8674(91)90384-b. [DOI] [PubMed] [Google Scholar]
  • 17.Xu J, et al. Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat Chem Biol. 2011;7:285–295. doi: 10.1038/nchembio.546. [DOI] [PubMed] [Google Scholar]
  • 18.Johnson SM, et al. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: A focus on the transthyretin amyloidoses. Acc Chem Res. 2005;38:911–921. doi: 10.1021/ar020073i. [DOI] [PubMed] [Google Scholar]
  • 19.Wilcken R, et al. Halogen-enriched fragment libraries as leads for drug rescue of mutant p53. J. Am. Chem. Soc. 2012;134:6810–6818. doi: 10.1021/ja301056a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Manno M, et al. Kinetics of different processes in human insulin amyloid formation. J Mol Biol. 2007;366:258–274. doi: 10.1016/j.jmb.2006.11.008. [DOI] [PubMed] [Google Scholar]
  • 21.Meuvis J, Gerard M, Desender L, Baekelandt V, Engelborghs Y. The conformation and the aggregation kinetics of alpha-synuclein depend on the proline residues in its C-terminal region. Biochemistry. 2010;49:9345–9352. doi: 10.1021/bi1010927. [DOI] [PubMed] [Google Scholar]
  • 22.Fersht A. Structure and Mechanism in Protein Science: A Guide to Enzyme Catalysis and Protein Folding. New York: W. H. Freeman; 1999. [Google Scholar]
  • 23.Wang G, Fersht AR. First-order rate-determining aggregation mechanism of p53 and its implications. Proc Natl Acad Sci USA. 2012 doi: 10.1073/pnas.1211557109. 10.1073/pnas.1211557109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Frieden C. Protein aggregation processes: In search of the mechanism. Protein Sci. 2007;16:2334–2344. doi: 10.1110/ps.073164107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Chen S, Ferrone FA, Wetzel R. Huntington’s disease age-of-onset linked to polyglutamine aggregation nucleation. Proc Natl Acad Sci USA. 2002;99:11884–11889. doi: 10.1073/pnas.182276099. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Bhattacharyya AM, Thakur AK, Wetzel R. polyglutamine aggregation nucleation: Thermodynamics of a highly unfavorable protein folding reaction. Proc Natl Acad Sci USA. 2005;102:15400–15405. doi: 10.1073/pnas.0501651102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Vitalis A, Pappu RV. Assessing the contribution of heterogeneous distributions of oligomers to aggregation mechanisms of polyglutamine peptides. Biophys Chem. 2011;159:14–23. doi: 10.1016/j.bpc.2011.04.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Kendrick BS, et al. Aggregation of recombinant human interferon gamma: Kinetics and structural transitions. J Pharm Sci. 1998;87:1069–1076. doi: 10.1021/js9801384. [DOI] [PubMed] [Google Scholar]
  • 29.Shukla AA, Gupta P, Han X. Protein aggregation kineticsduring Protein A chromatography. Case study for an Fc fusion protein. J Chromatogr A. 2007;1171:22–28. doi: 10.1016/j.chroma.2007.09.040. [DOI] [PubMed] [Google Scholar]
  • 30.Weijers M, Barneveld PA, Cohen Stuart MA, Visschers RW. Heat-induced denaturation and aggregation of ovalbumin at neutral pH described by irreversible first-order kinetics. Protein Sci. 2003;12:2693–2703. doi: 10.1110/ps.03242803. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Morris AM, Watzky MA, Agar JN, Finke RG. Fitting neurological protein aggregation kinetic data via a 2-step, minimal/“Ockham’s razor” model: The Finke–Watzky mechanism of nucleation followed by autocatalytic surface growth. Biochemistry. 2008;47:2413–2427. doi: 10.1021/bi701899y. [DOI] [PubMed] [Google Scholar]
  • 32.Morris AM, Watzky MA, Finke RG. Protein aggregation kinetics, mechanism, and curve-fitting: A review of the literature. Biochim Biophys Acta. 2009;1794:375–397. doi: 10.1016/j.bbapap.2008.10.016. [DOI] [PubMed] [Google Scholar]
  • 33.Solomon B, Koppel R, Hanan E, Katzav T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc Natl Acad Sci USA. 1996;93:452–455. doi: 10.1073/pnas.93.1.452. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supporting Information

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES